Ziad Abbud, MD
Interventional Cardiology · Ocean, NJNPI 1740373489
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $314,008 of the $360,488 with a category attached, or 87.1%. 57 manufacturers reported payments, led by Boehringer Ingelheim at 42.7% of the total. Reporting peaked in 2021 at $102,674 and has fallen 77.6% since, to $22,992 in 2025. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,492 payments — averaging $241.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$154K
- Esperion Therapeutics, Inc.$82K
- AstraZeneca$55K
- Cardiovascular Systems Inc.$31K
- Novartis$11K
- Lilly USA, LLC$7K
- plus $20K from 51 others
Across 1 payment — averaging $240.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$240
What the payments were for
- Consulting fees$7,5082%
- Speaking & faculty fees$314,00887%
- Travel & lodging$2,0231%
- Food & beverage$36,52810%
- Education$4220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$158,419
- NEXLIZET$81,415
- NEXLETOL$81,415
- FARXIGA$53,604
- Diamondback Peripheral$17,798
- ENTRESTO$8,174
- Peripheral Orbital Atherectomy System$7,711
- Coronary Orbital Atherectomy System$4,746
- Ozempic$4,500
- LEQVIO$1,363
- PRADAXA$520
- Assure WCD$397
- Acticor 7 VR-T DX$387
- BRILINTA$372
- SYMPLICITY G3$332
- BioMonitor$295
- Impella$289
- ESPRIT$173
- ONYX FRONTIER$168
- Diamondback Coronary$153
How this compares
$360,488 in reported general payments places this provider in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 795 | $907,781 |
| JardianceEmpagliflozin | 553 | $642,776 |
| XareltoRivaroxaban | 411 | $470,374 |
| EntrestoSacubitril/Valsartan | 336 | $408,271 |
| MultaqDronedarone Hcl | 242 | $308,107 |
| BrilintaTicagrelor | 299 | $270,464 |
| FarxigaDapagliflozin Propanediol | 246 | $245,469 |
| Repatha SureclickEvolocumab | 208 | $232,703 |
| NexletolBempedoic Acid | 118 | $94,760 |
| NexlizetBempedoic Acid/Ezetimibe | 82 | $74,004 |
| OzempicSemaglutide | 62 | $68,729 |
| Droxidopa | 13 | $57,157 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 131 | $43,026 |
| WegovySemaglutide | 28 | $38,298 |
| Praluent PenAlirocumab | 35 | $35,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lipitor | $143 | $914,769808 claims |
| Boehringer IngelheimJardiance | $153,749 | $642,776553 claims |
| AstraZenecaBrilinta, Farxiga, Crestor | $55,444 | $525,492557 claims |
| Johnson & JohnsonXarelto | $760 | $470,374411 claims |
| NovartisEntresto, Diovan | $10,593 | $419,122364 claims |
| Sanofi-aventis U.S. LLCMultaq | $546 | $308,107242 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $82,491 | $168,763200 claims |
| Novo NordiskOzempic, Wegovy | $4,998 | $107,02790 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $541 | $66,141147 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $161 | $7,76428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Ocean
- Ankitkumar PatelGlen Ridge$408K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
- Dimitrios KarmpaliotisMorristown$129K
- Sung-Han YoonHackensack$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.